Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit?
- PMID: 19942921
- DOI: 10.1038/nrclinonc.2009.170
Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit?
Abstract
Sunitinib is a standard first-line therapy for patients with advanced or metastatic clear-cell renal cell carcinoma. in an expanded-access study, sunitinib has demonstrated clinical benefit with an acceptable safety profile in a population of patients that is representative of those seen in clinical practice.
Comment on
-
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.Lancet Oncol. 2009 Aug;10(8):757-63. doi: 10.1016/S1470-2045(09)70162-7. Epub 2009 Jul 15. Lancet Oncol. 2009. PMID: 19615940 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
